Valeant's Siliq shows sustained effectiveness in moderate-to-severe psoriasis

Valeant Pharmaceutical’s subsidiary Ortho Dermatologics has released two-year findings from its Phase III study of Siliq for moderate-to-severe psoriasis.

The data show 59% of a sub-analysis group of patients experienced complete skin clearance.

At week 120, Siliq continued to be generally well-tolerated with a safety profile comparable to that observed at the 52-week point.

"Over a two-year trial, a PASI 100 response rate was reached by 59% of a sub-analysis group of patients, demonstrating that Siliq is a long-term option to treat moderate-to-severe psoriasis," said Alan Menter.

"This is highly important as patients always fear a flare-up of their psoriasis after initial clearing."